Last updated: March 10, 2026
What are the key facts of the case?
Pacira Pharmaceuticals sued the Research Development Foundation (RDF) in the District of Nevada on July 21, 2021, under case number 2:21-cv-02241-CDS-DJA. Pacira alleges that RDF engaged in patent infringement related to its injectable drug, EXPAREL, which uses the local anesthetic bupivacaine encapsulated in a liposomal formulation.
The complaint accuses RDF of violating patent rights associated with the drug's formulation, which are protected under U.S. patents held by Pacira. These patents are primarily related to the liposomal delivery system designed to prolong anesthetic effects.
What claims are made?
Pacira asserts patent infringement claims against RDF based on:
- Infringement of U.S. Patent Nos. 9,353,502 and 10,414,093.
- Willful infringement, seeking enhanced damages.
- Declaratory judgment of patent validity and enforceability.
RDF has yet to file an answer, and the case remains in early procedural stages.
What is the procedural posture?
The complaint was filed in federal court in Nevada. Pacira immediately moved for a preliminary injunction to prevent RDF from engaging in activities that allegedly infringe Pacira’s patents.
RDF responded by filing a motion to dismiss, arguing that Pacira’s patents are invalid for lack of novelty and inventive step. The court has not yet issued a decision on these motions.
What are the potential implications?
- Patent enforcement: Pacira aims to assert its patent rights to prevent RDF from manufacturing or selling similar liposomal formulations.
- Patent validity challenges: RDF’s arguments question the strength of Pacira’s patents, which could lead to invalidity findings.
- Market impact: Success for Pacira could solidify patent protections, maintaining exclusivity for EXPAREL’s formulation. A ruling favoring RDF could open the market, enabling generic or alternative formulations.
What are the notable legal issues?
- Patent validity: The core issue is whether Pacira’s liposomal formulation meets the criteria for patentability—novelty, non-obviousness, and utility.
- Infringement analysis: The case hinges on the comparison between RDF’s alleged manufacturing process and Pacira’s patented technology.
- Procedural matters: The timing and scope of preliminary injunctive relief and the potential for early settlement.
Status update as of the latest docket
As of the latest update, the court has not issued rulings on the preliminary injunction or RDF’s motion to dismiss. Discovery is set to proceed pending resolution of these issues.
Comparative context
Similar patent disputes in the pharmaceutical sector have resulted in:
| Case |
Outcome |
Impact |
| Amgen v. Sandoz (2017) |
Patent upheld |
Validated biosimilar patent protections |
| Gilead v. Natco (2020) |
Patent invalidated |
Opened pathways for generics |
| Regeneron v. Mylan (2021) |
Pending |
Ongoing patent infringement dispute |
This case aligns with the common trend of firm patent enforcement in biologic and drug formulations.
Conclusions
- The outcome depends heavily on the court’s assessment of the patents’ validity.
- Validity challenges based on prior art or obviousness could weaken Pacira’s claims.
- A favorable ruling for Pacira could reinforce its market position; a ruling favoring RDF could enable additional competition.
Key takeaways
- Litigation centers on established patent rights concerning liposomal drug formulations.
- Procedural stages and court rulings on preliminary injunctive relief and motions to dismiss will significantly influence case progression.
- The case reflects ongoing disputes over patent validity in complex drug delivery technologies.
FAQs
Q1: How long do patent infringement cases typically last?
It varies from 1 to 3 years, depending on discovery, motion practice, and settlement negotiations.
Q2: Can RDF’s defenses include prior art references?
Yes, RDF can argue that Pacira’s patents lack novelty or are obvious based on prior art.
Q3: What is the significance of a preliminary injunction in this case?
It could restrict RDF’s activities during the litigation, potentially impacting its market operations.
Q4: Are patent validity challenges common in pharmaceutical patent litigation?
Yes, challengers frequently argue patents are invalid, especially concerning obviousness and novelty.
Q5: How might recent court decisions influence this case?
Decisions on patent validity criteria, including applications of the Alice and Mayo standards, could impact the outcome.
References
- U.S. District Court, District of Nevada. (2021). Pacira Pharmaceuticals, Inc. v. Research Development Foundation, Case No. 2:21-cv-02241-CDS-DJA.
